What a buyer sees
LO'S PHARMACY LIMITED
Dispensing chemist in specialised stores · Rotherham · 03584267
74staff · FY2024
28years trading
64oldest owner on file
£16kcash at bank
Your turnover is on public record
filed£7.3Mfor the year to 2024
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff74
202273 → 742024
Cash at bank£16k
2022£224k → £16k2024
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£98,580in the bottom quarter
£95,753£142,090£223,271
Debtor daysdays27in the bottom quarter
263053
Creditor daysdays27
284463
Stock daysdays14in the bottom quarter
131935
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 2
- The newest accounts on file are 29 months oldAnyone looking at the company today is reading a year that has already ended. Whatever has improved since is invisible.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 3
- 28 years of trading on fileLongevity is the cheapest evidence there is that the business is not one contract.
- Debtor days better than three quarters of your tradeYours is 27 against 30 for the middle of 33 comparable companies.
- Stock days better than three quarters of your tradeYours is 14 against 19 for the middle of 38 comparable companies.
What the register says
Owners
- 64since 2016
- 61since 2016
Directors
- 64since 1998
- 61since 1998
- 29since 2022
- 32since 2022
| Year to | Turnover | Staff | Cash |
|---|---|---|---|
| 2024-03-31 | £7.3M | 74 | £16k |
| 2023-03-31 | £7.2M | 69 | £178k |
| 2022-03-31 | £7.0M | 73 | £224k |
A rough bracket, and why it is only that
0.25–0.5× sales£1.8M£3.6M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.